TELOMIUM

Telomium is a biotechnology company developing a cancer immunotherapy product with a unique composition in the present pharmacopoeia: a ribonucleoprotein, which has the ability to mimic a viral attack and induce an auto-immune reaction targeted against any form of cancer, without causing significant side effects. This self-vectored and self-adjuvanted vaccine is based on the telomerase ribonucleoprotein particle prepared from a patented, safe and competitive yeast-based technology using a breakthrough innovation in the production of the recombinant telomerase protein.